Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Quince Therapeutics, Inc.

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Participate at Upcoming Investor Conferences
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Launches Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Participate at Investor Events in January 2024
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.